MedicarePartD.guide

A non-government resource built from CMS public data

SGLT2 inhibitors on SilverScript Choice (S5601-006)

Jardiance, Farxiga and the other SGLT2 inhibitors, for diabetes, heart failure and kidney disease, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), New York
Premium
$116.00/month
Deductible
$615.00
Change plan

3 of 6 SGLT2 inhibitors are covered on this plan. None require prior authorization.

3 aren't on the formulary, including Invokana and Steglatro.

Not on the formulary
Invokana, Steglatro, Inpefa

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list